MINNEAPOLIS, Feb. 18,
2025 /PRNewswire/ -- Bio-Techne Corporation
(NASDAQ: TECH), a leading provider of innovative life science
research tools, is pleased to announce the official release of GMP
Transposase mRNA for the TcBuster™ non-viral genome engineering
system, supporting the development and manufacture of immune cell-
and stem cell-based therapies.
The TcBuster System has been widely used by researchers to
introduce large cargo genetic modifications in a range of cell
types. The new GMP transposase will offer a clearer path to clinic
for applications in gene edited cell therapies, such as CAR-T or
TCR generation.
Non-viral TcBuster offers numerous benefits over traditional
lentivirus-based engineering methods for cell therapy development.
The natural transposase has been enhanced through protein
engineering, resulting in a hyperactive enzyme. As a result,
multiple genes can be delivered from a GMP transposon
simultaneously while maintaining high editing efficiency and a
de-risked insertional profile. By negating the need for viral
clearance methods, the TcBuster system also significantly reduces
both the time to market and cost requirements for cell therapy
developers. Moreover, Bio-Techne has a strong and reliable supply
chain for both RUO & GMP grade reagents, including innovative
options for closed-system manufacturing, making it a dependable
option for scaling from research to clinical and commercial
stages.
"Our customers rely on us to help de-risk their cell therapy
manufacturing programs and support their scale up to clinical
trials and commercial manufacturing," said Will Geist, President Bio-Techne's Protein
Science Segment. "Releasing a GMP version of our TcBuster non-viral
genome engineering system marks a significant advance in meeting
that goal, providing cell therapy developers with a powerful tool
for efficient gene editing without the drawbacks of traditional
viral delivery systems."
The TcBuster system is compatible with a range of cell types,
including immune cells and stem cells, and can be used for a wide
range of applications, including autologous CAR-T or TCR
manufacturing, allogeneic NK therapies, and for engineering
bioprocessing cell lines for therapeutic biologics production.
The GMP TcBuster transposase is available now online at
www.bio-techne.com/tcbuster. For more information on the TcBuster
non-viral genome engineering system, please visit our website or
contact us directly.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With hundreds of thousands of products in its
portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has
approximately 3,100 employees worldwide. For more information on
Bio-Techne and its brands, please visit
http://www.bio-techne.com or follow the Company on social
media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-release-of-gmp-tcbuster-non-viral-genome-engineering-system-302376063.html
SOURCE Bio-Techne Corporation
